FIELD: chemistry.
SUBSTANCE: invention relates to a compound of structural formula 
having FGFR kinase inhibiting activity. In formula (I) R1 are identical or different from each other, and each is C1-C6alkyl; X1 and X2 are independently N or CH; R2 is hydrogen, C2-C6alkynyl, -C(=O)ORx, -C(=O)N(Rx)(Ry), hydroxy-C1-C6alkyl, di(C1-C6alkyl)amino-C1-C6alkkyl or a monocyclic or bicyclic C2-C9heteroaryl group containing 1-3 identical or different heteroatoms selected from a nitrogen, oxygen and sulphur atom, optionally containing R3; and R3 is C1-C6alkyl or di(C1-C6alkyl)amino-C1-C6alkyl; Z is -C(R4)=C(R5)(R6) or -C≡C-R7; Rx and Ry are identical or different from each other, and each is hydrogen, C1-C6alkyl, C3-C10cycloalkyl, di(C1-C6alkyl)amino-C1-C6alkyl or C1-C6alkoxy-C1-C6alkyl; l is an integer from 0 to 3; m is an integer from 1 to 3; and n is an integer from 0 to 2. Values of radicals Y, R4-R7 are given in the claim. The invention also relates to a pharmaceutical composition containing said compound, an anti-tumour agent and a tumour treatment method.
EFFECT: improved properties of compounds.
15 cl, 5 tbl, 73 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | 2014 |
|
RU2664118C2 |
| FGFR AND ITS MUTATION INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2811207C1 |
| NEW PYRROLOPYRIMIDINE COMPOUND OR ITS SALT, PHARMACEUTICAL COMPOSITION CONTAINING IT, IN PARTICULAR, AGENT FOR PREVENTION AND / OR TREATMENT OF TUMORS AND SO ON, BASED ON INHIBITING INFLUENCE ON NAE | 2015 |
|
RU2658008C2 |
| ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
| NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | 2014 |
|
RU2666349C2 |
| QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2015 |
|
RU2721723C2 |
| PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR | 2017 |
|
RU2714206C1 |
| NEW OXOISOQUINOLINE DERIVATIVES | 2017 |
|
RU2772226C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
| AGENT FOR PREVENTING AND/OR TREATING IMMUNE DISEASE | 2016 |
|
RU2705154C2 |
